• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

News

Article

Journal Digest: June 18, 2025

Key Takeaways

  • No significant association was found between vitamin D levels and rosacea in the Iranian study.
  • At-risk children with atopic dermatitis in Australia had more severe disease and higher healthcare utilization.
SHOW MORE

This review of the latest dermatologic studies includes insights into differences in vitamin D levels in rosacea versus healthy individuals, psychosocial determinants and atopic dermatitis outcomes, and more.

Dermatology Times Journal Digest logo

Journal of Cosmetic Dermatology: A Case–Control Study Examining the Differences in Vitamin D Levels Between Individuals With Rosacea and Healthy Individuals

A case–control study conducted in Iran compared vitamin D levels between 31 patients with rosacea and 31 healthy controls. Although mean vitamin D levels were higher in the rosacea group (29.9 ng/mL) than in controls (24.5 ng/mL), the difference was not statistically significant. Subgroup analysis by gender and rosacea severity also revealed no significant associations. Logistic regression adjusted for age showed no link between vitamin D levels and rosacea, suggesting no meaningful relationship between vitamin D status and the presence or severity of the condition.1

Australasian Journal of Dermatology: Psychosocial Determinants and Atopic Dermatitis Outcomes: A Cross-Sectional Study From an Australian Paediatric Centre

A retrospective cross-sectional study of 908 children with atopic dermatitis (AD) at a pediatric center in Melbourne found that those from at-risk groups—such as rural, culturally diverse, First Nations, socioeconomically disadvantaged, or vulnerable backgrounds—had significantly more severe disease (43.8% vs 28.3%) and greater health care use, including higher hospitalization and medication rates. Multivariate analysis showed these children had over 4 times the odds of severe AD and nearly 3 times the rate of hospitalizations compared to controls.2

JEADV Clinical Practice: Dermoscopic Evaluation of Erythema Versus Post-Inflammatory Hyperpigmentation (PIH) in Skin of Color (SOC) Patients

A clinical report highlighted how erythema may present differently in patients with skin of color, often appearing as brown or purple patches that are easily mistaken for post-inflammatory hyperpigmentation (PIH). Through the use of dermoscopy, clinicians can distinguish erythema from PIH by identifying a positive blanching effect—seen in inflammatory conditions like AD but absent in pigmentary disorders.3

Dermatologic Therapy: Clinical Efficacy and Safety of Upadacitinib Combined With a 308 nm Excimer Laser in the Treatment of Refractory Vitiligo Complicated With Atopic Dermatitis

A recent study in Chinese patients with refractory vitiligo and moderate to severe AD found that combining upadacitinib with 308-nm excimer laser therapy significantly improved outcomes. After 4 months, patients achieved a 55% reduction in Vitiligo Area Scoring Index, with the most notable repigmentation occurring on the face and neck (>70%). The hands and feet were least responsive. Improvements were also seen in AD severity (SCORAD ↓41.89%) and quality of life (DLQI ↓49.12%). No serious adverse events occurred.4

International Journal of Dermatology: Climate Change, Natural Disasters, and Cutaneous Fungal Infections

A retrospective study evaluated the use of VYC-12, a high–molecular weight hyaluronic acid injectable, in 15 adults with facial inflammatory skin conditions or aging-related concerns in Japan. Among 10 patients with treatment-resistant AD, acne vulgaris, or rosacea, VYC-12 significantly reduced skin redness and improved hydration over a 4-month period. All participants reported satisfaction with outcomes, and no adverse events occurred.5

References

  1. Faghihi G, Mohaghegh F, Shoushtarizadeh M, Poostiyan N, Hosseini SM, Khosravi A. A case–control study examining the differences in vitamin D levels between individuals with rosacea and healthy individuals. J Cosmet Dermatol. Published online June 10, 2025. doi:10.1111/jocd.70141
  2. Courtney A, Yazdabadi A, Schembri E, Lowe AJ, Williams C, Su JC. Psychosocial determinants and atopic dermatitis outcomes: A cross-sectional study from an Australian paediatric centre. Australas J Dermatol. Published online June 12, 2025. doi:10.1111/ajd.14547
  3. Parraga SP, Mayo TT. Dermoscopic evaluation of erythema versus post-inflammatory hyperpigmentation (PIH) in skin of color (SOC) patients. JEADV Clin Pract. Published online June 10, 2025. doi:10.1002/jvc2.70080
  4. Zhou F, Li W, Liu Y, Jin Q, Han W, Li J, Liu X. Clinical efficacy and safety of upadacitinib combined with a 308 nm excimer laser in the treatment of refractory vitiligo complicated with atopic dermatitis. Dermatol Ther. Published online June 16, 2025. doi:10.1155/dth/9949035
  5. Gupta AK, Thornbush M, Wang T. Climate change, natural disasters, and cutaneous fungal infections. Int J Dermatol. Published online June 12, 2025. doi:10.1111/ijd.17908

What new studies have you been involved with or authored? Share with us by emailing DTEditor@mmhgroup.com for an opportunity to be featured.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Videos
© 2025 MJH Life Sciences

All rights reserved.